Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Convertible Debt (2016 - 2017)

Lineage Cell Therapeutics' Convertible Debt history spans 4 years, with the latest figure at $1.9 million for Q4 2017.

  • For Q4 2017, Convertible Debt rose 80.72% year-over-year to $1.9 million; the TTM value through Dec 2017 reached $1.9 million, up 80.72%, while the annual FY2017 figure was $1.9 million, 80.72% up from the prior year.
  • Convertible Debt reached $1.9 million in Q4 2017 per LCTX's latest filing, up from $1.1 million in the prior quarter.
  • In the past five years, Convertible Debt ranged from a high of $1.9 million in Q4 2017 to a low of $60000.0 in Q4 2014.
  • Average Convertible Debt over 4 years is $741132.4, with a median of $617908.0 recorded in 2015.
  • Peak YoY movement for Convertible Debt: surged 440.0% in 2015, then decreased 26.33% in 2016.
  • A 4-year view of Convertible Debt shows it stood at $60000.0 in 2014, then soared by 440.0% to $324000.0 in 2015, then soared by 218.52% to $1.0 million in 2016, then skyrocketed by 80.72% to $1.9 million in 2017.
  • Per Business Quant, the three most recent readings for LCTX's Convertible Debt are $1.9 million (Q4 2017), $1.1 million (Q1 2017), and $1.0 million (Q4 2016).